American Century Companies Inc. Takes Position in Metsera Inc. $MTSR

American Century Companies Inc. acquired a new stake in Metsera Inc. (NASDAQ:MTSR) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 286,207 shares of the company’s stock, valued at approximately $7,791,000. American Century Companies Inc. owned about 0.27% of Metsera at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Alphabet Inc. bought a new stake in shares of Metsera in the 1st quarter valued at approximately $135,059,000. Vanguard Group Inc. bought a new stake in shares of Metsera in the 1st quarter valued at approximately $39,932,000. Massachusetts Financial Services Co. MA bought a new stake in shares of Metsera in the 1st quarter valued at approximately $13,111,000. Jennison Associates LLC bought a new stake in shares of Metsera in the 1st quarter valued at approximately $9,679,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Metsera in the 1st quarter valued at approximately $3,410,000.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on MTSR. Wells Fargo & Company began coverage on Metsera in a research note on Friday, June 20th. They issued an “overweight” rating and a $65.00 price objective for the company. Guggenheim raised their price objective on Metsera from $56.00 to $62.00 and gave the company a “buy” rating in a research note on Tuesday, June 10th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Metsera presently has an average rating of “Buy” and a consensus price target of $55.00.

Metsera Trading Up 5.5%

Shares of NASDAQ MTSR opened at $35.02 on Thursday. The business’s 50 day moving average price is $33.73 and its 200-day moving average price is $28.44. Metsera Inc. has a fifty-two week low of $12.30 and a fifty-two week high of $47.40.

Metsera (NASDAQ:MTSR) last issued its quarterly earnings results on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

Metsera Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.